Skip to Content

As GM Volt Sales Increase, That Doesn’t Mean It’s Successful

Sales of the car have improved, but not enough to turn the tide for advanced battery factories in the United States.
November 2, 2012

Sales figures for the Chevrolet Volt electric vehicle are in for October, and once again sales figures have increased dramatically compared to last year. Chevrolet sold 2,961 of the cars, compared to just 1,108 last October.

The Chevrolet Volt is interesting in part because anticipated sales of the car helped justify a massive, more-than-$2-billion-dollar push by the U.S. government to help companies build advanced lithium ion battery factories in the United States. But the companies that built those plants are struggling, in part because of lower than expected sales of cars like the Volt. A123 Systems recently declared bankruptcy (see, “A123’s Technology Just Wasn’t Good Enough” and “What Happened to A123?”). Dow said it would take an accounting charge because of a drop in value of its advanced battery venture, Dow Kokam. And LG Chem—which currently supplies battery cells for the Volt from a factory in Korea–has furloughed workers and hasn’t yet started building battery cells at a new factory in Holland, Michigan (see, “Too Many Battery Factories, Too Few Electric Cars”).

By some measures, the car is now doing well. About half of Chevrolet’s models sold more than the Volt, and about half sold less. It outsold the Corvette (1,167), for example. Sales accelerated this year after GM started offering attractive lease rates ($199 a month).

But the Volt far undersold the Cruze (19,121), a sedan about the size of the Volt. And GM isn’t coming close to a goal, set at the end of last year, to sell 60,000 Volts this year.

And most crucially, the factory LG Chem built to make batteries for the Volt in Holland, Michigan, still isn’t making batteries.  

Yet it’s too early to write off plug-in hybrids and electric cars. Many automakers have just started to introduce battery-powered cars.  Toyota’s Prius also had a slow start, and now it’s become a centerpiece of Toyota’s strategy—and a profitable car. 

Keep Reading

Most Popular

This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

VR is as good as psychedelics at helping people reach transcendence

On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.